How should gallbladder polyps be managed in a patient without coexisting gallstones?

Management of Gallbladder Polyps Without Coexisting Gallstones

Manage gallbladder polyps based on size alone, as coexisting gallstones do not influence malignancy risk or alter management decisions. 1

Key Principle: Gallstones Are Irrelevant

The presence or absence of gallstones should not change your approach to gallbladder polyps. The 2022 Society of Radiologists in Ultrasound (SRU) consensus explicitly states that despite the ubiquity of gallstones, they do not correlate with either malignancy or benignity in polyps 1. This is critical because it simplifies management—you can ignore gallstone status entirely and focus solely on polyp characteristics.

Size-Based Management Algorithm

Polyps ≥15 mm

• Refer for surgical consultation immediately 1
• Size ≥15 mm is an independent risk factor for neoplastic lesions
• Neoplastic polyps average 18.5 mm vs 12.6 mm for non-neoplastic polyps

Polyps 10-14 mm

• Consider surgical consultation based on:
  • Patient risk factors (age >60 years, PSC, Asian ethnicity, sessile morphology)
  • Evidence of growth on follow-up imaging 1, 2
• The 2022 European guidelines recommend cholecystectomy for polyps ≥10 mm if the patient is fit for surgery 2

Polyps 6-9 mm

• Ultrasound surveillance at 6 months, 1 year, and 2 years if risk factors present 2
• Risk factors include: age >60 years, PSC history, Asian ethnicity, sessile morphology
• Without risk factors: same surveillance schedule recommended
• Malignancy rate is only 8.7 per 100,000 patients in this size range 1

Polyps ≤5 mm

• No follow-up required 1, 2
• Zero documented malignancies in multiple large studies
• 12-year follow-up study of 154 patients with polyps <6 mm showed no gallbladder cancers 1
• Up to 83% of apparent polyps ≤5 mm are not found at subsequent cholecystectomy 1

Important Caveats

Growth does not necessarily indicate malignancy. Small polyps commonly grow 2-3 mm as part of their natural history—two-thirds of polyps <6 mm show growth over 10 years, yet none developed cancer 1. Only refer for surgery if growth reaches the 10 mm threshold or if rapid growth occurs with concerning features.

Focal wall thickening >4 mm is higher risk. Neoplastic lesions are more likely to present as focal wall thickening (37.9% of cancers) rather than protruding polyps (15.9% of cancers) 1. Treat focal wall thickening ≥4 mm as a risk factor.

Discontinue surveillance after 2 years if stable 2. The evidence shows that prolonged follow-up beyond 2 years in stable, small polyps without risk factors leads to unnecessary healthcare costs (>$118,000 in one study) without improving outcomes 3.

Primary sclerosing cholangitis changes everything. Do not apply these guidelines to PSC patients—they have 18-50% malignancy rates in gallbladder lesions and require specialty gastroenterology guidelines 1.

What NOT to Consider

• Age alone should not drive decisions (no clear threshold improves survival) 1
• Smoking, diabetes, obesity do not sufficiently increase absolute risk to change management 1
• Sex (despite 2-6x higher GBC incidence in women, absolute risk remains too low) 1
• Symptoms warrant cholecystectomy regardless of size if no alternative cause exists 2

The evidence is clear: in the absence of gallstones, your management is identical to patients with gallstones—size is the primary determinant of risk, with the overall malignancy rate being extraordinarily low (0.4% even in polyps >10 mm) 1.